Ting Chao Chou

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
    Ting Chao Chou
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Pharmacol Rev 58:621-81. 2006
  2. ncbi Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice
    Ting Chao Chou
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021, USA
    Cancer Chemother Pharmacol 56:379-90. 2005
  3. doi Preclinical versus clinical drug combination studies
    Ting Chao Chou
    Laboratory of Preclinical Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Leuk Lymphoma 49:2059-80. 2008
  4. doi Drug combination studies and their synergy quantification using the Chou-Talalay method
    Ting Chao Chou
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 70:440-6. 2010
  5. doi The mass-action law based algorithms for quantitative econo-green bio-research
    Ting Chao Chou
    Preclinical Pharmacology Core Laboratory, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Integr Biol (Camb) 3:548-59. 2011
  6. ncbi Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route
    Ting Chao Chou
    Preclinical Pharmacology and Analytical Chemistry Core Laboratories, and Bio Organic Chemistry Laboratory, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center
    Cancer Res 65:9445-54. 2005
  7. pmc Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma
    Prasad S Adusumilli
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Biol Ther 5:48-53. 2006
  8. pmc Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer
    Prasad S Adusumilli
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Thorac Surg 80:409-16; discussion 416-7. 2005
  9. ncbi Complex target-oriented total synthesis in the drug discovery process: the discovery of a highly promising family of second generation epothilones
    Alexey Rivkin
    Laboratory for Bioorganic Chemistry, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, New York 10021, USA
    J Am Chem Soc 125:2899-901. 2003
  10. ncbi Synthesis and conformational analysis of (E)-9,10-dehydroepothilone B: a suggestive link between the chemistry and biology of epothilones
    Fumihiko Yoshimura
    Laboratory for Bioorganic Chemistry, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021, USA
    Angew Chem Int Ed Engl 42:2518-21. 2003

Collaborators

Detail Information

Publications44

  1. ncbi Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
    Ting Chao Chou
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Pharmacol Rev 58:621-81. 2006
    ....
  2. ncbi Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice
    Ting Chao Chou
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021, USA
    Cancer Chemother Pharmacol 56:379-90. 2005
    ....
  3. doi Preclinical versus clinical drug combination studies
    Ting Chao Chou
    Laboratory of Preclinical Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Leuk Lymphoma 49:2059-80. 2008
    ....
  4. doi Drug combination studies and their synergy quantification using the Chou-Talalay method
    Ting Chao Chou
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 70:440-6. 2010
    ..This theory also provides algorithms for automated computer simulation for synergism and/or antagonism at any effect and dose level, as shown in the CI plot and isobologram, respectively...
  5. doi The mass-action law based algorithms for quantitative econo-green bio-research
    Ting Chao Chou
    Preclinical Pharmacology Core Laboratory, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Integr Biol (Camb) 3:548-59. 2011
    ..It is concluded that the contemporary biomedical sciences would greatly benefit from the mass-action law based "Green Revolution"...
  6. ncbi Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route
    Ting Chao Chou
    Preclinical Pharmacology and Analytical Chemistry Core Laboratories, and Bio Organic Chemistry Laboratory, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center
    Cancer Res 65:9445-54. 2005
    ..4 months. The above results indicate that Fludelone is a highly promising compound for cancer chemotherapeutics...
  7. pmc Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma
    Prasad S Adusumilli
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Biol Ther 5:48-53. 2006
    ..We hypothesized that cisplatin upregulates GADD34 expression, which enhances NV1066 replication and oncolysis...
  8. pmc Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer
    Prasad S Adusumilli
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Thorac Surg 80:409-16; discussion 416-7. 2005
    ..We hypothesized that radiation therapy may potentiate efficacy of oncolytic viral therapy by upregulating GADD34 and promoting viral replication...
  9. ncbi Complex target-oriented total synthesis in the drug discovery process: the discovery of a highly promising family of second generation epothilones
    Alexey Rivkin
    Laboratory for Bioorganic Chemistry, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, New York 10021, USA
    J Am Chem Soc 125:2899-901. 2003
    ..From the perspective of compound availability through synthesis, potency, and pharmacokinetic properties, these compounds could well warrant advancement to clinical evaluation in humans...
  10. ncbi Synthesis and conformational analysis of (E)-9,10-dehydroepothilone B: a suggestive link between the chemistry and biology of epothilones
    Fumihiko Yoshimura
    Laboratory for Bioorganic Chemistry, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021, USA
    Angew Chem Int Ed Engl 42:2518-21. 2003
  11. pmc 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer
    David P Eisenberg
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Gastrointest Surg 9:1068-77; discussion 1077-9. 2005
    ..These data provide the cellular basis for the clinical investigation of combined oncolytic herpes virus therapy and chemotherapy in the treatment of pancreatic cancer...
  12. ncbi Discovery of (E)-9,10-dehydroepothilones through chemical synthesis: on the emergence of 26-trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a promising anticancer drug candidate
    Alexey Rivkin
    Contribution from the Laboratory for Bioorganic Chemistry, Preclinical Pharmacology Core Facility, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021, USA
    J Am Chem Soc 126:10913-22. 2004
    ..These results have identified compound 7 as a particularly promising compound for clinical development. The excellent, totally synthetic, route to 7 makes such a program quite feasible...
  13. ncbi Design and total synthesis of a superior family of epothilone analogues, which eliminate xenograft tumors to a nonrelapsable state
    Ting Chao Chou
    Preclinical Pharmacology Core Facility, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021, USA
    Angew Chem Int Ed Engl 42:4762-7. 2003
  14. ncbi Total syntheses of [17]- and [18]dehydrodesoxyepothilones B via a concise ring-closing metathesis-based strategy: correlation of ring size with biological activity in the epothilone series
    Alexey Rivkin
    Laboratory for Bioorganic Chemistry, Preclinical Pharmacology Core Facility and Analytical Pharmacology Core Facility, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, New York 10021, USA
    J Org Chem 67:7737-40. 2002
    ..In contrast, the biological data revealed that [18]ddEpoB is significantly less active than either [17]ddEpoB or the parent [16]ddEpoB...
  15. ncbi Highly concise routes to epothilones: the total synthesis and evaluation of epothilone 490
    Kaustav Biswas
    Bioorganic Chemistry, Preclinical Pharmacology Core Facility and Analytical Pharmacology Core Facility, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, New York 10021, USA
    J Am Chem Soc 124:9825-32. 2002
    ..This disappointing outcome was traced to unfavorable pharmacokinetic features of the drug in murine plasma. By the pharmacokinetic criteria, the prognosis for the effectiveness of 3 in humans is, in principle, much more promising...
  16. ncbi Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207)
    Joseph J Bennett
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    FASEB J 18:1001-3. 2004
    ..5 HSV mutants in the treatment of cancer...
  17. ncbi Total synthesis as a resource in drug discovery: the first in vivo evaluation of panaxytriol and its derivatives
    Heedong Yun
    Department of Chemistry, Columbia University, 3000 Broadway, New York, New York, 10027, USA
    J Org Chem 70:10375-80. 2005
    ..Finally, preliminary in vitro evaluation of panaxytriol indicates that it possesses neurotrophic activity...
  18. pmc Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones
    Ting Chao Chou
    Preclinical Pharmacology Laboratory, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:13157-62. 2008
    ..In addition, iso-fludelone was shown to exhibit a significant therapeutic effect against an intracranially implanted SK-NAS tumor...
  19. pmc Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma
    Michael Mullerad
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 174:741-6. 2005
    ....
  20. ncbi Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma
    Prasad S Adusumilli
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 14:258-69. 2007
    ..Such stress response is beneficial for oncolytic viral therapy. We hypothesized that a combination of RT and NV1066, an oncolytic herpes virus, might exert an additive or synergistic effect in the treatment of MPM...
  21. pmc Multifaceted cytoprotection by synthetic polyacetylenes inspired by the ginseng-derived natural product, panaxytriol
    Ting Chao Chou
    Preclinical Pharmacology Core Facility and Bio Organic Laboratory, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 108:14336-41. 2011
    ..The studies described herein suggest that coadministration of a PXT-derived agent with cancer chemotherapeutics or radiation therapy may serve to mitigate a range of therapy-associated toxicities...
  22. ncbi Probing the SAR of dEpoB via chemical synthesis: a total synthesis evaluation of C26-(1,3-dioxolanyl)-12,13-desoxyepothilone B
    Mark D Chappell
    Laboratories for Bioorganic Chemistry and Laboratories for Preclinical Pharmacology, The Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, New York 10021, USA
    J Org Chem 67:7730-6. 2002
    ..Sufficient amounts of synthetic 26-dioxolane dEpoB were produced using this sequence for an in vivo analysis in mice containing xenograft CCRF-CEM tumors...
  23. ncbi Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo
    Naoto Takahashi
    Program of Molecular Pharmacology and Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:6909-15. 2002
    ..These results suggest that the combination of ET-743 and paclitaxel should be assessed in clinical trials for the treatment of breast cancer...
  24. pmc Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer
    Shu Fu Lin
    Department of Surgery and Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:1519-28. 2008
    ..We studied the application of oncolytic herpes simplex virus (G207 and NV1023) in combination with currently used chemotherapeutic drugs (paclitaxel and doxorubicin) for the treatment of ATC...
  25. ncbi On the introduction of a trifluoromethyl substituent in the epothilone setting: chemical issues related to ring forming olefin metathesis and earliest biological findings
    Alexey Rivkin
    Laboratories for Bioorganic Chemistry, Sloan Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021, USA
    Org Lett 4:4081-4. 2002
    ..reaction: see text]..
  26. pmc p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas
    Bhuvanesh Singh
    Laboratory of Epithelial Cancer Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genes Dev 16:984-93. 2002
    ..Thus, p53 regulates cell survival by inhibiting the PI3K/AKT prosurvival signal independent of PTEN in epithelial tumors. This inhibition is required for p53-mediated apoptosis in malignant cells...
  27. pmc 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1
    Archie N Tse
    Laboratory of New Drug Development, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mol Pharmacol 75:124-33. 2009
    ..Taken together, 17AAG specifically inhibits the G(2)/M checkpoint in p53-defective cells by down-regulation of two critical checkpoint kinases, Chk1 and Wee1...
  28. pmc Synthesis of pluraflavin A "aglycone"
    Benjamin J D Wright
    Department of Chemistry, Columbia University, Havemeyer Hall, 3000 Broadway, New York, New York 10027, USA
    J Am Chem Soc 130:16786-90. 2008
    ..The preliminary in vitro results of two such compounds are also included with the racemic title compound exhibiting cytotoxicity in the nanomolar range...
  29. doi Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage
    Naval Kapuriya
    Institute of Biomedical Sciences, Laboratory of Bioorganic Chemistry, Academia Sinica, Taipei 115, Taiwan
    Bioorg Med Chem 16:5413-23. 2008
    ..It also showed that 24d was capable of inducing marked dose-dependent levels of DNA cross-linking by comet assay and has long half-life in rat plasma...
  30. ncbi Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation
    Kamesh Rastogi
    Laboratory of Bioorganic Chemistry, Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan
    J Med Chem 45:4485-93. 2002
    ..Studies on the inhibitory effect against topoisomerase II (Topo II) and DNA interaction of these conjugates showed no correlation between the potency of DNA binding and inhibitory activity against Topo II...
  31. ncbi Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural pattern--synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives
    Ling He
    West China School of Pharmacy, Sichuan University, Chengdu 610041, China
    Eur J Med Chem 38:101-7. 2003
    ....
  32. ncbi Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity
    Tsann Long Su
    Laboratory of Bioorganic Chemistry, Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan
    J Med Chem 49:3710-8. 2006
    ..Of these agents, compounds 27a and 27c were shown to have potent antitumor activity in nude mice bearing the human breast carcinoma MX-1 xenograft. The therapeutic efficacies of these two agents are comparable to that of taxol...
  33. ncbi Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel
    Chih Chuan Chang
    Department of Biology, Johns Hopkins University, 3400 N Charles Street, Baltimore, MD 21218, USA
    Cancer Chemother Pharmacol 58:640-53. 2006
    ..Multidrug resistance (MDR) continues to be a major obstacle for successful anticancer therapy. One of the principal factors implicated in MDR is the over expression of P-glycoprotein (Pgp), the product of the MDR1 gene...
  34. ncbi Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells
    Tieran Han
    Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, 33101, USA
    J Cancer Res Clin Oncol 131:609-16. 2005
    ..The demonstration that araC and CdA combinations exert synergistic cytotoxicity even in the resistant cells raises hope that such a combination may be useful in tumors that were found resistant to these drugs...
  35. ncbi Synthesis and antitumor activity of 5-(9-acridinylamino)anisidine derivatives
    Valeriy A Bacherikov
    Laboratory of Bioorganic Chemistry, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
    Bioorg Med Chem 13:6513-20. 2005
    ..AOA (15e) was the most potent among these derivatives, which resulted in 60% suppression of tumor volume at a dose of 20 mg/kg (Q2D x 9), intravenous injection on day 26 in nude mice bearing human breast carcinoma MX-1 xenografts...
  36. ncbi New analogues of AHMA as potential antitumor agents: synthesis and biological activity
    Jang Yang Chang
    Division of Cancer Research, National Health Research Institutes, Taipei, Taiwan
    Bioorg Med Chem 11:4959-69. 2003
    ..e., 21c, 23c and 26c) were more cytotoxic than AHMA (1) and AHMA-ethylcarbamate (2), depending upon the tumor cell line tested. Detailed structure-activity relationships of the new analogues were studied...
  37. ncbi Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation
    Valeriy A Bacherikov
    Laboratory of Bioorganic Chemistry, Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan
    Bioorg Med Chem Lett 14:4719-22. 2004
    ....
  38. ncbi Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity
    Valeriy A Bacherikov
    Laboratory of Bioorganic Chemistry, Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan
    Bioorg Med Chem 13:3993-4006. 2005
    ..Furthermore, 10 yielded xenograft tumor suppression of 81-96% using human T-cell acute lymphoblastic leukemia CCRF-CEM, colon carcinoma HCT-116, and ovarian adenocarcinoma SK-OV-3 tumor models...
  39. ncbi Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells
    Carsten Muller-Tidow
    Department of Medicine, Hematology Oncology, University of Munster, Albert Schweitzer Strasse 33, D 48129 Munster, Germany
    Int J Oncol 23:151-8. 2003
    ..Our in vitro model suggests further investigations are required of the potential value of HMG-CoA reductase inhibitors as adjunct to therapy of CML with interferon...
  40. ncbi Enhanced hydrolytic stability and water solubility of an aromatic nitrogen mustard by conjugation with molecular umbrellas
    Saketh Vijayaraghavan
    Department of Chemistry, Lehigh University, Bethlehem, Pennsylvania 18015, USA
    Bioconjug Chem 14:667-71. 2003
    ..In vitro studies indicate that these conjugates possess modest to moderate activity against certain human lymphoblastic leukemia and human colon carcinoma cells...
  41. pmc TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, 65 Landsdowne St, Room 419, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 49:3483-5. 2005
    ..Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted...
  42. ncbi TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro
    Cecile L Tremblay
    Antivir Ther 10:967-8. 2005
  43. pmc Synergy determination issues
    Ting Chao Chou
    J Virol 76:10577; author reply 10578. 2002
  44. ncbi 2-Chloro-2'-deoxyadenosine synergistically enhances azidothymidine cytotoxicity in azidothymidine resistant T-lymphoid cells
    Tieran Han
    Division of Hematology Oncology, Department of Medicine M862, P O Box 019132, University of Miami School of Medicine, Miami, FL 33101, USA
    Biochem Biophys Res Commun 316:518-22. 2004
    ..These findings suggest the potential usefulness of a double-targeted approach for designing efficacious therapeutics for the kinase deficient drug resistant tumors...